About us
Genase Therapeutics was incubated by the Dutch life sciences VC fund BioGeneration Ventures in 2019. The company builds upon novel DHODH inhibitors that were discovered by prof. Sonia Lain and colleagues of the Karolinska Institute for the treatment of cancer.
Genase therapeutics exploits metabolic vulnerabilities in tough to treat oncogene addicted cancers
We assembled a strong and experienced team with deep expertise in oncology drug development to execute on our mission to exploit metabolic vulnerabilities in oncogene addicted cancers. The team previously navigated the development of multiple oncology drugs from the preclinical stage to the market.
DHODH fuels oncogenic signaling pathways
Genase Therapeutics develops small molecule inhibitors of dihydroorotate dehydrogenase (DHODH), a critical enzyme in de novo pyrimidine biosynthesis and electron transport. DHODH links mitochondrial bioenergetics, cell proliferation, ROS production, and apoptosis. Building on the discovery of a novel DHODH inhibitor by prof. Sonia Lain and colleagues of the Karolinska Institute, the team has generated a unique and highly potent development candidate ready to enter IND-enabling studies.